At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 43 enrolled
Drug / intervention
IONIS-GHR-LRx +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS-GHR-LRx, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks in Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands (SRL)
In Brief
A Phase 2 clinical trial evaluating IONIS-GHR-LRx and Placebo for Acromegaly. Completed, enrolled 43 participants across 33 sites in 7 countries.
Detailed Summary
The purpose of this study was to assess the safety, tolerability, and efficacy of IONIS-GHR-LRx in up to 60 participants with acromegaly.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesHungary, Lithuania, Poland, Romania, Russia, Serbia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartSep 2018
Primary CompletionFeb 2021
Study CompletionApr 2021
TodayJul 2026
First PostedJun 7, 2018
Enrollment StartSep 13, 2018
Primary CompletionFeb 18, 2021
Study CompletionApr 2, 2021
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 8.1 years ago
Interventions
IONIS-GHR-LRxdrug
IONIS GHR-LRx administered subcutaneously.
Placebodrug
Placebo administered subcutaneously.